APA (7th ed.) Citation

Reifsnider, O. S., Kansal, A. R., Franke, J., Lee, J., George, J. T., Brückmann, M., . . . Hau, N. (2020). Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. ESC heart failure, 7(6), . https://doi.org/10.1002/ehf2.12985

Chicago Style (17th ed.) Citation

Reifsnider, Odette S., et al. "Cost-effectiveness of Empagliflozin in the UK in an EMPA-REG OUTCOME Subgroup with Type 2 Diabetes and Heart Failure." ESC Heart Failure 7, no. 6 (2020). https://doi.org/10.1002/ehf2.12985.

MLA (9th ed.) Citation

Reifsnider, Odette S., et al. "Cost-effectiveness of Empagliflozin in the UK in an EMPA-REG OUTCOME Subgroup with Type 2 Diabetes and Heart Failure." ESC Heart Failure, vol. 7, no. 6, 2020, https://doi.org/10.1002/ehf2.12985.